Status:
COMPLETED
Suprainguinal Fascia Iliaca Block Versus PENG Block for Hip Arthroplasty Analgesia
Lead Sponsor:
University of Chile
Conditions:
Postoperative Complications
Postoperative Pain
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
In recent years, suprainguinal fascia iliaca block (SFIB) has emerged as a reliable analgesic option for primary total hip arthroplasty (THA). In 2018, a new block was described, termed pericapsular n...
Eligibility Criteria
Inclusion
- Age between 18 and 80 years
- American Society of Anesthesiologists classification 1-3
- Body mass index between 20 and 35 (kg/m2)
Exclusion
- Adults who are unable to give their own consent
- Pre-existing neuropathy (assessed by history and physical examination)
- Coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤a100, International Normalized Ratio ≥01.4 or prothrombin time ≥ 50)
- Renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100)
- Hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100)
- Allergy to local anesthetics (LAs)
- Pregnancy
- Prior surgery in the corresponding side of the inguinal or suprainguinal area
- Chronic pain syndromes requiring opioid intake at home
Key Trial Info
Start Date :
August 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04402450
Start Date
August 31 2020
End Date
May 28 2021
Last Update
September 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clínico Universidad de Chile
Santiago, Metropolitan, Chile, 8380456